Image Results
No matches found.
Video Results
No matches found.
Web Results
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | Next | Last
Definition of BMS-354825 - NCI Dictionary of Cancer Terms (Search Map)
BMS-354825 is also being studied in the treatment of certain other blood ... BMS-354825 binds to and blocks BCR-ABL and other proteins that help cancer cells ...
BMS-354825 Overcomes Imatinib Resistance in CML - Cancer Network (Search Map)
Like imatinib, BMS-354825 is a kinase inhibitor, but it is less specific, ... Not only does BMS-354825 have immediate application for patients with imatinib ...
Identification of Pharmacogenomic Markers for Predicting Sensitivity to ... (Search Map)
Identification of Pharmacogenomic Markers for Predicting Sensitivity to BMS-354825, a SRC/ABL Kinase Inhibitor - ASCO - The American Society of Clinical Oncology ...
SYNOPSIS (Search Map)
BMS-354825 Clinical. Study. Report. Name of Sponsor/Company: ... TITLE OF STUDY: A Phase I Dose-Escalation Study of BMS-354825 in Patients with Refractory Solid ...
DASATINIB (BMS-354825) ONCOLOGIC DRUG ADVISORY COMMITTEE (ODAC ... (Search Map)
BMS-354825. Advisory Committee Briefing Document. 02-June-2006 Bristol ... Dasatinib (BMS-354825) is a potent oral inhibitor of multiple oncogenic kinases ...
SYNOPSIS (Search Map)
TITLE OF STUDY: A Randomized Multicenter Open Label Study of BMS-354825 vs Imatinib Mesylate ... BMS-354825. Final Clinical Study Report. multiplying the MMR ...
Study of BMS-354825 in Patients With Chronic Myeloid Leukemia Who Are ... (Search Map)
Purpose The purpose of this study is to see what effect an investigational drug (BMS-354825) has on subjects who are in chronic phase Philadelphia chromosome ...
BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous ... (Search Map)
RATIONALE: BMS-354825 may stop the growth of cancer cells by stopping the ... Patients receive oral BMS-354825 once daily on days 1-5. Courses repeat every 7 ...
Identification of pharmacogenomic markers for predicting sensitivity to ... (Search Map)
Background: BMS-354825 is a SRC/ABL kinase inhibitor currently in clinical ... cancer cell lines for which sensitivity (IC50) to BMS-354825 was pre-determined. ...
BMS-354825 in Treating Patients With Blastic Phase Chronic Myelogenous ... (Search Map)
Purpose RATIONALE: BMS-354825 may stop the growth of cancer cells by blocking ... A Phase II Study of BMS-354825 in Subjects With Myeloid Blast Phase Chronic ...